Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world

Background: The long-term efficacy of low-dose aspirin for primary prevention of cardiovascular (CV) events in postmenopausal women with type-2 diabetes is controversial. Therefore, it is recommended only on an individual basis, recommendation of grade C. Methods: We enrolled 275 consecutive postmen...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Maria Maiello, Annagrazia Cecere, Annapaola Zito, Marco Matteo Ciccone, Pasquale Palmiero
Formato:	article
Lenguaje:	EN
Publicado:	Wolters Kluwer Medknow Publications 2021
Materias:	cardiovascular events low-dose aspirin postmenopausal women primary prevention type-2 diabetes Medicine R
Acceso en línea:	https://doaj.org/article/ccbc46979cd146509dfe680faff16fe6
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:ccbc46979cd146509dfe680faff16fe6
record_format	dspace
spelling	oai:doaj.org-article:ccbc46979cd146509dfe680faff16fe62021-11-12T10:11:33ZLow-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world2008-78022008-821310.4103/ijpvm.IJPVM_365_19https://doaj.org/article/ccbc46979cd146509dfe680faff16fe62021-01-01T00:00:00Zhttp://www.ijpvmjournal.net/article.asp?issn=2008-7802;year=2021;volume=12;issue=1;spage=140;epage=140;aulast=Maiellohttps://doaj.org/toc/2008-7802https://doaj.org/toc/2008-8213Background: The long-term efficacy of low-dose aspirin for primary prevention of cardiovascular (CV) events in postmenopausal women with type-2 diabetes is controversial. Therefore, it is recommended only on an individual basis, recommendation of grade C. Methods: We enrolled 275 consecutive postmenopausal women with type-2 diabetes, without an increased bleeding risk and without preexisting CV disease as coronary artery disease, stroke, and peripheral vascular disease, but with a high risk assessed by score >10%, aged 60–69 years. All were receiving aspirin (75–100 mg daily), aspirin group (AG). 170 postmenopausal women with type-2 diabetes and without preexisting cardiovascular (CV) disease, but not on aspirin treatment, despite a high risk assessed by score >10%, were control group (CG). Mean age was 66 ± 4 years for AG and 65 ± 7 years for CG. Our goal was to identify the prevalence of low-dose aspirin prescriptions in these populations according to different clinical conditions. Results: Women with only high risk were 41/275 (15%) on AG and 72/170 (42.3%) on CG, Chi-squared 41, Odds ratio 0.2, c.i. 95%, P < 0.0001. Women affected by metabolic syndrome were 105/275 (38.1%) on AG and 47/170 (27.6%) on CG, Chi-squared 5.1, Odds ratio 1.6, c.i. 95%, P < 0.02. Women affected by metabolic cardiomyopathy were 111/275 (40.3%) on AG and 44/170 (25.9%) on CG, Chi-squared 8, Odds ratio 1.8, c.i. 95%, P < 0.004. Women affected by diabetic cardiomyopathy were 18/275 (6.6%) on AG and 7/170 (4.2%) on CG, Chi-squared 1.2, Odds ratio 16, c.i. 95%, P < 0.2 n.s. Conclusions: Low-dose aspirin in our population is prescribed preferentially in postmenopausal women with type-2 diabetes when affected by metabolic syndrome or metabolic cardiomyopathy, at the opposite women with only high risk have lower chance to receive aspirin.Maria MaielloAnnagrazia CecereAnnapaola ZitoMarco Matteo CicconePasquale PalmieroWolters Kluwer Medknow Publicationsarticle cardiovascular eventslow-dose aspirinpostmenopausal womenprimary preventiontype-2 diabetes MedicineRENInternational Journal of Preventive Medicine, Vol 12, Iss 1, Pp 140-140 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cardiovascular events low-dose aspirin postmenopausal women primary prevention type-2 diabetes Medicine R
spellingShingle	cardiovascular events low-dose aspirin postmenopausal women primary prevention type-2 diabetes Medicine R Maria Maiello Annagrazia Cecere Annapaola Zito Marco Matteo Ciccone Pasquale Palmiero Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world
description	Background: The long-term efficacy of low-dose aspirin for primary prevention of cardiovascular (CV) events in postmenopausal women with type-2 diabetes is controversial. Therefore, it is recommended only on an individual basis, recommendation of grade C. Methods: We enrolled 275 consecutive postmenopausal women with type-2 diabetes, without an increased bleeding risk and without preexisting CV disease as coronary artery disease, stroke, and peripheral vascular disease, but with a high risk assessed by score >10%, aged 60–69 years. All were receiving aspirin (75–100 mg daily), aspirin group (AG). 170 postmenopausal women with type-2 diabetes and without preexisting cardiovascular (CV) disease, but not on aspirin treatment, despite a high risk assessed by score >10%, were control group (CG). Mean age was 66 ± 4 years for AG and 65 ± 7 years for CG. Our goal was to identify the prevalence of low-dose aspirin prescriptions in these populations according to different clinical conditions. Results: Women with only high risk were 41/275 (15%) on AG and 72/170 (42.3%) on CG, Chi-squared 41, Odds ratio 0.2, c.i. 95%, P < 0.0001. Women affected by metabolic syndrome were 105/275 (38.1%) on AG and 47/170 (27.6%) on CG, Chi-squared 5.1, Odds ratio 1.6, c.i. 95%, P < 0.02. Women affected by metabolic cardiomyopathy were 111/275 (40.3%) on AG and 44/170 (25.9%) on CG, Chi-squared 8, Odds ratio 1.8, c.i. 95%, P < 0.004. Women affected by diabetic cardiomyopathy were 18/275 (6.6%) on AG and 7/170 (4.2%) on CG, Chi-squared 1.2, Odds ratio 16, c.i. 95%, P < 0.2 n.s. Conclusions: Low-dose aspirin in our population is prescribed preferentially in postmenopausal women with type-2 diabetes when affected by metabolic syndrome or metabolic cardiomyopathy, at the opposite women with only high risk have lower chance to receive aspirin.
format	article
author	Maria Maiello Annagrazia Cecere Annapaola Zito Marco Matteo Ciccone Pasquale Palmiero
author_facet	Maria Maiello Annagrazia Cecere Annapaola Zito Marco Matteo Ciccone Pasquale Palmiero
author_sort	Maria Maiello
title	Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world
title_short	Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world
title_full	Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world
title_fullStr	Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world
title_full_unstemmed	Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world
title_sort	low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: the prescriptive approach in the real world
publisher	Wolters Kluwer Medknow Publications
publishDate	2021
url	https://doaj.org/article/ccbc46979cd146509dfe680faff16fe6
work_keys_str_mv	AT mariamaiello lowdoseaspirinforprimarypreventionofcardiovasculareventsinpostmenopausalwomenwithtype2diabetestheprescriptiveapproachintherealworld AT annagraziacecere lowdoseaspirinforprimarypreventionofcardiovasculareventsinpostmenopausalwomenwithtype2diabetestheprescriptiveapproachintherealworld AT annapaolazito lowdoseaspirinforprimarypreventionofcardiovasculareventsinpostmenopausalwomenwithtype2diabetestheprescriptiveapproachintherealworld AT marcomatteociccone lowdoseaspirinforprimarypreventionofcardiovasculareventsinpostmenopausalwomenwithtype2diabetestheprescriptiveapproachintherealworld AT pasqualepalmiero lowdoseaspirinforprimarypreventionofcardiovasculareventsinpostmenopausalwomenwithtype2diabetestheprescriptiveapproachintherealworld
_version_	1718431018973659136

Low-dose aspirin for primary prevention of cardiovascular events in postmenopausal women with type-2 diabetes: The prescriptive approach in the real world

Ejemplares similares